-
Product Insights
NewTreatment Resistant Depression – Drugs In Development, 2024
Empower your strategies with our Treatment Resistant Depression – Drugs In Development, 2024 report and make more profitable business decisions. Treatment-resistant depression (TRD) refers to a form of depression that does not adequately respond to standard treatments, such as antidepressant medications or psychotherapy, even after multiple trials of different therapies. It can be a challenging and distressing condition for individuals experiencing persistent depressive symptoms. Some common characteristics of treatment-resistant depression include inadequate response to antidepressants; persistent symptoms, which can include feelings...
-
Product Insights
NewAppetite (Eating) Disorders – Drugs In Development, 2024
Empower your strategies with our Appetite (Eating) Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Appetite (eating) disorders are psychological conditions that affect how people think and behave regarding food and their body weight and shape. They can cause serious health problems and even death if not treated. Some of the most common types are anorexia nervosa, bulimia nervosa, binge-eating disorder, and avoidant restrictive food intake disorder. People with these disorders may have symptoms such as...
-
Product Insights
NewAutism Spectrum Disorder (ASD) – Drugs In Development, 2024
Empower your strategies with our Autism Spectrum Disorder (ASD) – Drugs In Development, 2024 report and make more profitable business decisions. Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. Symptoms range from mild to severe, forming a spectrum. Individuals with ASD may have difficulties in understanding social cues, expressing emotions, and engaging in reciprocal conversations. Sensory sensitivities are common, affecting responses to stimuli. Early intervention and tailored support can enhance communication...
-
Product Insights
NewMajor Depressive Disorder – Drugs In Development, 2024
Empower your strategies with our Major Depressive Disorder – Drugs In Development, 2024 report and make more profitable business decisions. Major Depressive Disorder (MDD) is a common and severe mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in daily activities. Symptoms may include changes in appetite and sleep patterns, fatigue, difficulty concentrating, feelings of worthlessness, and thoughts of death or suicide. Diagnosis is based on the duration and intensity of these symptoms....
-
Product Insights
NewAnorexia Nervosa – Drugs In Development, 2024
Empower your strategies with our Anorexia Nervosa – Drugs In Development, 2024 report and make more profitable business decisions. Anorexia nervosa is an eating disorder defined by restriction of energy intake relative to requirements, leading to a significantly low body weight. Patients will have an intense fear of gaining weight and distorted body image with the inability to recognize the seriousness of their significantly low body weight. The Anorexia Nervosa drugs in development market research report provide comprehensive information on the...
-
Product Insights
NewNet Present Value Model: Compass Pathways Plc’s Psilocybin
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Major Depressive Disorder
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Psilocybin in Major Depressive Disorder Drug Details: Psilocybin is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STK-012 in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STK-012 in Metastatic Melanoma Drug Details: STK-012 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CTX-471 in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CTX-471 in Malignant Mesothelioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CTX-471 in Malignant Mesothelioma Drug Details:CTX-471 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Anorexia Nervosa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Anorexia Nervosa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Psilocybin in Anorexia Nervosa Drug Details: Psilocybin is under development for the...